AkilMerchantMD Profile Banner
Akil Merchant Profile
Akil Merchant

@AkilMerchantMD

Followers
238
Following
13
Media
9
Statuses
175

Interests in Cancer, Immunotherapy, Lymphoma, CART, Bone Marrow Transplantation and spatial profiling of tumor microenvironment.

Los Angeles, CA
Joined October 2015
Don't wanna be here? Send us removal request.
@QasimRashid
Qasim Rashid, Esq.
4 months
If Zohran Mamdani becomes NYC mayor at the age of 33 it will be a death blow to millions of young south Asian men in this country. Every desi parent is gonna be like, “Zohran was Mayor of New York City at 33! You haven’t even bought a house yet! Why can’t you be more like
713
5K
99K
@CancerNetwrk
CancerNetwork®
4 months
In the third or later lines of treatment for those with R/R LBCL, LYL314 led to an ORR of 88% and a CR rate of 72%, with 71% of those patients remaining in a CR for 6 or more months. #lymsm https://t.co/osORQZHnW9
cancernetwork.com
LYL314 elicited a complete response rate of 72%, with 71% of responses lasting for 6 or more months in patients with large B-cell lymphoma in the third or later lines of therapy.
0
1
0
@rtnarch
Robert Nelsen
5 months
Lyell far ahead of JNJ and Kite CD19/20, many more patients, treating an apparently much sicker group, showing longer durability, looks like favorable tox. The days of CD19 alone are over. CD19/20 wins, and JNJ, KITE are behind. (ARCH was the first venture backer of Carl June
@MarcJacksonLA
stock setter
5 months
$LYEL - Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma - https://t.co/YHyi9zoJb7
1
1
29
@AkilMerchantMD
Akil Merchant
1 year
Hey @elonmusk and @VivekGRamaswamy, single payer health care is clearly the most efficient. Love to see DOGE promote that. Time to cut out the insurance companies and pharmacy benefit managers who just suck money and effort out of the system.
0
0
1
@moorejh
Jason H. Moore, PhD
1 year
Cedars-Sinai Establishes Health Sciences University including new PhD Program in Health Artificial Intelligence! Please RT! https://t.co/jZf4ak2TrS #artificialintelligence
1
11
21
@CMECedarsSinai
CME Program at Cedars-Sinai
1 year
Thank you to everyone who joined us for the 2024 Research Updates in Lymphoma conference at @CedarsSinai on Sept 28-29! We appreciate the national experts who shared their insights on cutting-edge treatments and groundbreaking research in lymphoma care. #LymphomaResearch
0
4
4
@KazeraniMaryam
Maryam Kazerani
1 year
Excited to share that the 2024 Research Updates in Lymphoma was a fantastic success! We enjoyed excellent presentations, insightful discussions, and explored novel techniques and future research opportunities in #lymphoma transformation. @AkilMerchantMD @AshAlizadeh
1
5
7
@CMECedarsSinai
CME Program at Cedars-Sinai
1 year
Concluding the 2024 Research Updates in Lymphoma with a Lunch Time Round Table on Major Knowledge Gaps and Research Opportunities in Transformed Lymphoma. Thank you to our dedicated faculty and attendees, both in-person and virtual, for making this a successful event!
0
5
8
@schroersmartin
Joe Schroers-Martin, MD
1 year
Presenting an overview with Ranjana Advani of the current role of brentuximab and the checkpoint inhibitors in classic Hodgkin lymphoma: https://t.co/S41rWnAZcx Thanks to @JCOOP_ASCO for a great review & publication process.
Tweet card summary image
ascopubs.org
Classic Hodgkin lymphoma (cHL) is highly curable at all stages. Research efforts over the past few decades have largely focused on interim PET-adapted strategies for therapy de-escalation or intens...
0
3
17
@moorejh
Jason H. Moore, PhD
1 year
Are you looking for a PhD program in health AI embedded in a top US hospital with access to clinical data & physicians? Check out our new PhD program at Cedars-Sinai Medical Center in LA https://t.co/8BGZEhpctz #phd #artificialintelligence #Bioinformatics
cedars-sinai.edu
1
17
40
@NeBanovich
Nick Banovich
1 year
Earlier this week we carried out a preliminary analysis of our first @10xGenomics Xenium prime (5,000 gene) run. We had designed this experiment to get a sense of how the prime chemistry performed compared to the Xenium V1 chemistry.
@NeBanovich
Nick Banovich
1 year
First @10xGenomics Xenium 5K run!
7
34
104
@alexmxu
Alex Xu
2 years
We used IMC to look at primary, metastatic, recurrent ovarian cancer - an understudied cancer overall but tissue is widely available. Side note, published panels are years behind. Can’t speak for all but in this study of ours at least, we can and are doing much better.
1
4
6
@alexmxu
Alex Xu
2 years
Hello spatial bio folks! Happy to announce the 2nd Annual Cedars-Sinai Spatial Biology Symposium, next Thursday March 7! RSVP to join us in LA in person or virtually, for spatial this, spatial that, and all the spatial others! https://t.co/BmaoiBrpZw
2
11
29
@CSRegenMedicine
Regenerative Medicine Institute at Cedars-Sinai
2 years
Save the Date📝: The Cedars-Sinai Spatial Biology Symposium will take place on March 7, focusing on Cancer, Stem Cells & Development, and Neuroscience. RSVP for in-person attendance and submit a trainee lightning talk abstract here: https://t.co/l2cf0dOfnW
0
8
12
@jnkath
Jakob Nikolas Kather
2 years
Happy to share our latest paper by @ElNahhasOSM et al., which was just published in @NatureComms! This work presents a new method which improves the prediction of biomarkers from routine pathology slides. https://t.co/NPUhaf4tpn @tudresden_de @katherlab @Medizin_TUD
7
24
188
@CSCancerCenter
Cancer at Cedars-Sinai
2 years
Dr. Akil Merchant @AkilMerchantMD is co-senior author on a Journal of Clinical Oncology paper using innovative #spatialprofiling techniques to predict if #cancer of the immune system recurs in patients treated with a #bonemarrowtransplant. @JCO_ASCO
cedars-sinai.org
Cedars-Sinai Cancer investigators have discovered a new way to predict whether a cancer of the immune system will recur in patients treated with a bone marrow transplant. Their study, published in...
0
4
9